What were the breakthrough results reported by IDEAYA Biosciences (NASDAQ:IDYA)?

IDEAYA and its partner Servier announced that their Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma (MUM) met its primary endpoint. The combination of darovasertib and crizotinib more than doubled the time patients lived without the disease progressing compared to traditional chemotherapy. Specifically, patients on the combination therapy saw a median progression-free survival (PFS) of 6.9 months versus 3.1 months for the control group.

Why is this news significant for the treatment of uveal melanoma?

The trial focused on patients with a specific genetic profile (HLA-A*02:01-negative) who currently have no FDA-approved targeted therapies. Because the combination therapy demonstrated a 58% reduction in the risk of disease progression or death, it is being positioned as a potential new standard of care. For investors, this represents a significant market opportunity in a "high unmet need" oncology niche.

How did the stock market react to the IDEAYA Biosciences (NASDAQ:IDYA) trial data?

Shares of IDEAYA Biosciences surged approximately 27% in early trading following the announcement. The jump reflects investor confidence in the drug's "registrational" data, meaning the results are strong enough to support a formal marketing application. Traders are viewing this as a major de-risking event for the company’s lead clinical program.

What is the next major regulatory milestone for darovasertib?

IDEAYA plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026. The company is seeking "accelerated approval" based on these results, which could allow the drug to reach the market faster than a standard review process. Investors should watch for the official filing announcement as the next major catalyst for the stock.

What are the key "bull" points for investors after this news?

The bull case is supported by a high Objective Response Rate (ORR) of 37.1%, which included five complete responses—a rare achievement in this aggressive cancer. Additionally, the drug showed a "manageable" safety profile with mostly mild side effects. From a financial perspective, IDEAYA reported a strong cash position of approximately $1.05 billion at the start of 2026, which provides a long "runway" to fund a potential commercial launch.

IDEAYA announces positive Phase 2/3 data in metastatic uveal melanoma

Written by Mahathir BayenaPublished Apr. 13 2026Last Updated Apr. 13 2026

IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported breakthrough topline results today from the Phase 2/3 OptimUM-02 trial, demonstrating that the combination of darovasertib and crizotinib significantly improved outcomes for patients with first-line HLA-A*02:01-negative metastatic uveal melanoma (MUM).

The data establishes the combination as a potential new standard of care for a patient population with historically limited treatment options.

The registrational trial reached its primary endpoint with high statistical significance.

Patients treated with the darovasertib and crizotinib combination achieved a median progression-free survival (PFS) of 6.9 months, compared to just 3.1 months for those receiving investigator’s choice of chemotherapy.

This represents a 58% reduction in the risk of disease progression or death (HR 0.42; 95% CI 0.30-0.59; p<0.0001).

Beyond the delay in disease progression, the combination showed robust anti-tumor activity.

The confirmed Objective Response Rate (ORR) was 37.1% in the combination arm—including five complete responses—versus a meager 5.8% in the control arm (p<0.0001).

The median duration of response (DOR) was recorded at 6.8 months.

Meanwhile, the safety profile of the combination remained consistent with previous Phase 2 findings.

Most treatment-related adverse events (TRAEs) were Grade 1 or 2, and serious TRAEs occurred in only a single-digit percentage of patients.

The most common side effects included gastrointestinal issues and skin rash, which were managed through standard supportive care and dose adjustments.